Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
April 25, 2024 07:00 ET
|
Morphic Therapeutic
MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
March 19, 2024 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Morphic Therapeutic
Morphic CEO. Praveen Tipirneni, MD, to present at JP Morgan Healthcare Conference January 10, 2024